Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

Advanced Nonhematologic Malignancies Clinical Trial

Official title:
A Multicenter, Open-label, Phase 1b Study of TAK-733 (an Oral MEK Inhibitor) in Combination With Alisertib (an Oral Aurora A Kinase Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies

Status Withdrawn

Clinical Trial Summary

This is a Multicenter, Open-label, Phase 1b Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Advanced Nonhematologic Malignancies
Neoplasms

Clinical Trial Details

NCT number	NCT01613261
Study type	Interventional
Source	Millennium Pharmaceuticals, Inc.
Contact
Status	Withdrawn
Phase	Phase 1
Start date	August 2013
Completion date	November 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01204073` - A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies	Phase 1
Completed	`NCT01899053` - A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies	Phase 1
Completed	`NCT02327169` - A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies	Phase 1
Completed	`NCT00677170` - Study of MLN4924 in Adult Patients With Nonhematologic Malignancies	Phase 1